Endocrine Pharmacology:
|
|
- Everett Bertram Skinner
- 6 years ago
- Views:
Transcription
1 Endocrine Pharmacology: Part 1: Hypothalamus/Pituitary, Pineal, Thyroid/ Parathyroid, Adrenals, Ovaries/Testes Part 2: Diabetes mellitus types 1 & 2 PHRM 203 Allison Beale
2 Types of Diabetes D. mellitus Type I (Juvenile onset) Pancreas not producing enough insulin, must take insulin Type II (Non-insulin dependant diabetes mellitus, NIDDM) Usually insulin resistance, but may be not enough insulin Gestational Diabetes Placental hormones cause insulin resistance in mom Cystic fibrosis Diabetes Shared characteristics with Type I and II DM D. insipidus Problem with ADH (usually, pituitary or kidney issue) A Beale PHRM Endocrine 2
3 Pancreas is a combination of exocrine and endocrine glands Ducted (exocrine) gland Digestive enzymes secreted into small intestine Ductless (endocrine) gland Insulin Glucose out of blood Glucagon Glucose into blood A Beale PHRM Endocrine 3
4 Conditions that affect glycemic control Management of Hospitalized Patients with Type 2 diabetes Mellitus, SH Lilley and GI Levine, AAFP, 1 March 1998 Hyperglycemia ( [gl] blood ) Excessive food intake Physical activity Pancreatic disease Infection Ischemia/infarction Trauma Surgery Emotional stress Pregnancy (2 nd /3 rd T) Cirrhosis (liver disease) Hypoglycemia ( [gl] blood ) Dietary intake Physical activity Malabsorption Alcohol intake Adrenocortical insufficiency Renal insufficiency Hepatic failure Pregnancy (1 st T) Gastrectomy A Beale PHRM Endocrine 4
5 Drugs with diabetes interactions Drug Glucosamine Risperidone (Risperdal, an atypical antipsychotic) SSRIs Interaction May increase insulin resistance Linked to type 2 DM, pancreatitis Patients report hypoglycemia Low Blood Sugar Symptoms Headache, dizziness, hunger, confusion, trouble concentrating, weakness, nausea, blurred vision, drowsiness, rapid heart rate, sweating, tremors Severe Hypoglycemia Symptoms Confusion, stomach pain, trouble speaking, extreme weakness, blurred vision, sweating, tremors, seizures, coma Hyperglycemia Symptoms Thirst, loss of appetite, nausea, increased urination, vomiting, drowsiness, dry mouth, dry skin A Beale PHRM Endocrine 5
6 Drugs with diabetes interactions Drugs that blood glucose Cause HYPERGLYCEMIA Drugs that blood glucose Cause HYPOGLYCEMIA Glucagon Diuretics Insulin Sympathomimetics Ethanol (chronic) Oral antihyperglycemic agents Amphetamines Glucocorticosteroids Ethanol (acute use) β Blockers β Agonists Pentamidine (initially) Cyclosporins Growth hormone Pentamidine Diazoxide Niacin Salicylates (hi-dose) Management of Hospitalized Patients with Type 2 diabetes Mellitus, SH Lilley and GI Levine, AAFP, 1 March 1998 A Beale PHRM Endocrine 6
7 Drugs with possible diabetes interactions Drugs that may blood glucose Caffeine CCBs ACE - I Drugs that may blood glucose Clonidine Estrogen/progestins Anabolic steroids Isoniazid Nicotine Aspirin (high doses) Octreotide Phenothiazines Disopyramide (Norpace) Phenytoin Rifampin Ganciclovir, saquinavir Management of Hospitalized Patients with Type 2 diabetes Mellitus, SH Lilley and GI Levine, AAFP, 1 March 1998 Quinine (high doses) Sulfonamides Patients on SSRIs often report hypoglycemia A Beale PHRM Endocrine 7
8 Ketoacidosis If cells can t take up glucose (DMT1), or if glucose is unavailable, respiration shifts to fatty acid oxidation Fatty acids produce acidic lactones when burned Very high blood glucose treated with insulin VERY HIGH or VERY LOW blood sugar Thirst Fruity breath Vomiting Dehydration Deep, gasping breath Confusion Dry, flushed skin Coma and death A Beale PHRM Endocrine 8
9 Parenteral Antihyperglycemic Drug Insulin (human Humulin R or Novolin R)! Indication Diabetes mellitus (all types), treatment of severe ketoacidosis, hyperkalemia, gestational diabetes. Expect nighttime hypoglycemia, especially in DMT2 patients when using insulin and/or insulin analogs. SC, IV, IM Short acting, used if eating minutes after injection R = Regular Which means, Human Top 4 drugs associated with medication errors: 1. Insulin 2. Morphine 3. Fentanyl 4. Tie: Metoprolol, Albuterol & Potassium chloride A Beale PHRM Endocrine 9
10 What about other routes? Insulin is a protein Subject to extensive and rapid metabolism Afrezza (human insulin of rdna origin) Previously called Afresa Nasal inhalation powder Approved 2014 Image: Huffington Post A Beale PHRM Endocrine 10
11 Types of insulin Aspart Detemir Glargine Glulisine Lispro Isophane (NPH) intermediate form produced by chemically combining insulin with protamine and zinc Regular - recombinant Zinc intermediate form. Zinc polymerizes the insulin making it last longer. Analogs produced by making slight changes to amino acid sequence. Some like Glargine are also complexed with zinc. These changes alter the kinetics. Analog, Beef or Pork analog = recombinant, beef/ pork isolated at slaughter (rarely used now) Human - recombinant Analog or Pork Novolog Levemir Lantus Apidra Humalog Humulin N Novolin N Relion Novolin N Iletin NPH Insulin Purified NPH Pork Humulin R Novolin R Iletin II Regular (Ultralente) Iletin Lente Iletin Lente Pork Lente Iletin II Novolin L A Beale PHRM Endocrine 11
12 Onset of action for Insulin types Rapid-Acting - for meals eaten at time of injection, typically used with longer-acting form Drug Onset (minutes) Peak (hours) Duration (hours) Lispro (Humalog)! Novolog or Aspart Short-Acting - for meals eaten within minutes of injection 3-5 Regular (R ) (Humulin R)! Intermediate-Acting - for overnight, or about 1/2 the day. Usually combined with above forms. Neutral Protamine Hagedorn - NPH (N)! (Humulin N) 1-2 hours 4-12 Lente (Humulin L)! hours Long-Acting - covers insulin needs for an entire day. May be combined with rapid/short form. Glargine (Lantus)! 1-3 hours A Beale PHRM Endocrine 12
13 1 st Generation Sulfonylureas Oral sulfonylureas stimulate the pancreas to secrete insulin Secretagogues Drug Chlorpropamide (Diabinese)! Tolazamide Tolbutamide Indication Adjunct to diet and exercise for type 2 DM If taking a sulfonylurea, patient must have a functional pancreas and be able to recognize and respond to symptoms of hypoglycemia Table adapted from: Focus on Nursing Pharmacology, 4th Ed., by AM Karch. Lippincott, Williams & Wilkins A Beale PHRM Endocrine 13
14 2 nd Generation Sulfonylureas Oral sulfonylureas can cause severe hypoglycemia & risk of CV death Drug Glimepiride Glipizide Glyburide (Micronase)! Indication Adjunct to diet and exercise for type 2 DM 1 st generation sulfonylureas are water soluble and less potent than 2 nd generation sulfonylureas which are lipid soluble. Table adapted from: Focus on Nursing Pharmacology, 4th Ed., by AM Karch. Lippincott, Williams & Wilkins A Beale PHRM Endocrine 14
15 Sulfonylureas ADRs SIADH G6PD Risk of CV death Hypoglycemia risk Blood dyscrasias Disulfiram-like rxns GI upset Dizziness, headache Drugs that hypoglycemic risk w/sulfonylureas NSAIDs & other highly PPB drugs Salicylates Sulfonamides Chloramphenicol Probenecid Coumarins MAOIs β blockers Other antidiabetes drugs Including the Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors Canaglifozin (Invokana) Empagliflozin (Jardiance) A Beale PHRM Endocrine 15
16 Nonsulfonylureas Drug Metformin (Glucophage)! Pioglitazone (Actos)! Indication Biguanide Adjunct to diet & exercise for DMT2, also treats polycystic ovary syndrome Does not cause hypoglycemia and protects against CV effects of diabetes. Works mainly by hepatic gluconeogenesis. PPARγ agonist Adjunct to diet & exercise for DMT2 in combo with insulin or sulfonylureas to control blood sugar when one drug alone won t work NEW FDA WARNING: RISK OF BLADDER CANCER A Beale PHRM Endocrine 16
17 Metformin (Glucophage)! Hypoglycemic action Ketoconazole Erythromycin Chloramphenicol NSAIDs, salicylates Probenecid Warfarin Lactic acidosis action Corticosteroids Estrogens INH Phenytoin Thiazides Glucose control destabilized by β blockers PO, SID/BID with meals Quinolones Thyroid hormone Need functional kidneys A Beale PHRM Endocrine 17
18 Pioglitazone (Actos)! Insulin must be present It insulin resistance Activation of PPARγ nuclear receptors modulates transcription of several insulin responsive genes involved in the control of glucose and lipid metabolism. Indicated as an adjunct to diet & exercise to improve glycemic control in adults with type 2 DM ADRs Hypoglycemia risk Edema Weight gain May trigger ovulation Congestive HF PO, SID A Beale PHRM Endocrine 18
19 Nonsulfonylureas Drug Sitagliptin (Januvia)! Indication DPP4 inhibitor - Adjunct to diet & exercise for type 2 diabetes. Acts by inhibiting the enzyme, dipeptidyl peptidase 4, that breaks down incretins (glucagon-like peptide and glucose-dependant insulinotropic polypeptide) Exenatide (Byetta) Liraglutide (Victoza)! Think: Lizard spit Incretin mimics - Adjunct to diet & exercise for type 2 diabetes. Increase insulin secretion, decrease glucagon secretion and gastric emptying time. Boxed warning (Victoza) for thyroid cancer risk. Table adapted from: Focus on Nursing Pharmacology, 4th Ed., by AM Karch. Lippincott, Williams & Wilkins A Beale PHRM Endocrine 19
20 Sitagliptin (Januvia)! Janumet = sitagliptin + metformin ADRs Risk of hypoglycemia Pancreatitis Serious allergic rxns Upper RTI Nasopharyngitis Headache PO, SID Blocks the breakdown of incretins Dipeptidyl peptidase-4 (DPP4) inhibitor Incretins function to: glucagon secretion gastric emptying time appetite insulin secretion A Beale PHRM Endocrine 20
21 Liraglutide (Victoza)! Glucagon-like Peptide-1 (GLP-1) receptor agonist ADRs Severe hypoglycemia risk with sulfonylureas Headache Nausea Diarrhea Anti-liraglutide Ab SC, SID Regardless of meals Causes slow weight loss Hypothalmus interaction Glucose-dependent Only insulin in the presence of glucose Thyroid cancer seen in rodents A Beale PHRM Endocrine 21
22 Nonsulfonylureas Drug Bromocriptine (Cycloset)! Indication Ergot alkaloid, Dopamine agonist Adjunct to diet & exercise for DMT2 Must be given within 2 hours of waking PO, SID May cause nausea, hypotension, somnolence, and worsening of psychotic conditions Canaglifozin (Invokana)! SGLT2 inhibitor PO, SID Adjunct to diet & exercise for DMT2 Also given 1 st thing in the morning, before eating May cause bacterial/fungal UTIs, hypotension, hyperkalemia, hypoglycemia, increased LDL-C A Beale PHRM Endocrine 22
23 Other Diabetes medications Acarbose (Precose)! α-glucosidase inhibitor (inhibits carbohydrate digestion and absorption) - Helps prevent rapid glucose rise after eating. Indication: adjunct to diet and exercise to improve glycemic control in adults with DMT2 PO, up to TID with meals Should be taken with first bite of each meal. wt. gain and insulinotropic effects of sulfonylureas, but since CBH remain in GIT, microbes ferment the CBHs producing GAS A Beale PHRM Endocrine 23
24 Other Diabetes medications Drug Indication T2DM /comments Pramlintide (Symlin) Amylin analog - Adjunct to type 1 or 2 diabetes using meal-time insulin but without glycemic control Repaglinide (Prandon) Insulin secretagogue (stimulates the pancreas to secrete more insulin, similar to sulfonylureas) - Increases circulating insulin. Take tablet(s) with meals. A Beale PHRM Endocrine 24
25 Glucose elevating agents Drug Diazoxide Glucagon (Glucagen)! Indication Oral management of hypoglycemia, IV for severe hypertension Injectable to control severe hypoglycemic reactions (increases blood glucose and relax GIT smooth muscle) Table adapted from: Focus on Nursing Pharmacology, 4th Ed., by AM Karch. Lippincott, Williams & Wilkins A Beale PHRM Endocrine 25
26 Glucose elevating agents Glucagon (Glucagen)! rdna Polypeptide hormone Exogenous glucagon stimulates catecholamine release Must have sufficient liver glycogen. It won t work in states of: Starvation Adrenal insufficiency Chronic hypoglycemia Indications 1. Treatment of severe hypoglycemia 2. As a diagnostic aid in the radiologic exam of GIT when reduced GIT motility is needed. SC, IV, IM A Beale PHRM Endocrine 26
27 Other Endocrine Glands Gland Stomach Small intestine Heart Placenta Hormone Gastrin Stimulates gastric acid & digestive enzyme release Secretin Stimulates pancreas to release bicarb Cholecystokinin Stimulates gall bladder contractions Atrial natriuretic hormone ADH release Chorionic gonadotropin Stimulates ovaries to maintain pregnancy A Beale PHRM Endocrine 27
Endo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationOral and Injectable Medication Options for Diabetes Treatment
Oral and Injectable Medication Options for Diabetes Treatment Presented by: Dr. Daphne E. Smith, Pharm.D., CDE Clinical Assistant Professor/Clinical Pharmacist-University of Illinois at Chicago College
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationAntidiabetic Agents CHAPTER BIGUANIDES
ajt/shutterstock, Inc. CHAPTER 2 Antidiabetic Agents Charles Ruchalski, PharmD, BCPS BIGUANIDES For newly diagnosed patients with type 2 diabetes, the biguanide metformin is the drug of choice for initial
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationDiabetes Mellitus. Raja Nursing Instructor. Acknowledgement: Badil 09/03/2016
Diabetes Mellitus Raja Nursing Instructor 09/03/2016 Acknowledgement: Badil Objective: Define Diabetes Mellitus (DM) & types of DM. Understand the pathophysiology of Type-I & II DM. List the clinical features
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationSoliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow
Soliqua 100/33 (insulin glargine, lixisenatide) New Product Slideshow Introduction Brand name: Soliqua 100/33 Generic name: Insulin glargine (rdna origin), lixisenatide Pharmacological class: Human insulin
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationNon-Insulin Diabetes Medications Summary
Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential
More informationHow to Fight Diabetes and Win. Diabetes. Medications
How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to
More informationEndocrine. Hormones secreted from glands. Gonads
Pharmacology 203 Windward Community College Endocrine Hormones secreted from glands Glands we will discuss Hypothalamus/pituitary Thyroid & Parathyroid Pancreas Adrenals Pineal Gonads Hypothalamus and
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationNormal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),
Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationThe Community Pharmacist s Role in Diabetes Treatment
CONTINUING EDUCATION The Community Pharmacist s Role in Diabetes Treatment By Kimberly Ference, PharmD U pon completion of this activity, the pharmacist should be able to achieve these directives: 1. Describe
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationINSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.
INSULIN OVERVIEW Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro Humalog 15-30 min 30-90 min 3-5 hrs aspart glulisine Short-Acting Regular insulin NovoLog Apidra
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationCare of patients with endocrine system disorders
King Saud University College of Nursing Medical Surgical Department Application of Adult Health Nursing Skills ( NUR 317 ) Care of patients with endocrine system disorders Prepared by Mrs: Alwah M. Alkathiri
More informationDiabetes Treatment Guidelines
Diabetes Treatment Guidelines For more comprehensive information about current approaches to the diagnosis and treatment of diabetes, visit the American Diabetes Association Standards of Medical Care 2018
More informationSupplementary Online Content
Supplementary Online Content Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Internal
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationMetformin Hydrochloride
Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationHistory of Investigation
Acini - Pancreatic juice (1º) (2º) Secretions- neuronal and hormonal mechanisms 1) Secretin - bicarbonate rich 2) Cholecystokinin - enzyme rich Islets of Langerhans (contain 4 cell types) Alpha cells (α)-
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationAnti-Diabetic. Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin. Exocrine gland that produces digestive enzymes.
Anti-Diabetic The pancreas : Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin Exocrine gland that produces digestive enzymes. The peptide hormones are secreted from cells
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationRebecca Newberry APRN MS CDE
Current Diabetes Medications Nursing Implications and Applications Rebecca Newberry APRN MS CDE Methodist Center for Diabetes and Nutritional Health Disclosures Objectives Speakers Bureaus/Consulting Board
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationType. Diabetes Drugs. A Review
Type Diabetes is a common diagnosis for home care patients. Diabetes drugs are now available that target the multiple defects of metabolism that characterize Type 2 diabetes. Understanding the wide variety
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationQuick Guide MEDICATIONS 7th Edition Evan Sisson, Pharm.D., MHA, CDE
Quick Guide to MEDICATIONS 7th Edition Evan Sisson, Pharm.D., MHA, CDE Adapted from The Art and Science of Diabetes Self-Management Education Desk Reference 2017, American Association of Diabetes Educators,
More information2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care
Hey Sugar! DMII Management in Hospice Care Michelle Huber, R.Ph., PharmD.,CGP Objectives Review treatment for hyperglycemia discussing how these medications work, hypoglycemia risk, special considerations.
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More information1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime
Disclosures Current Diabetes Medications None Claire Baker, M.D. Diabetes & Endocrine Associates January 24, 2018 Objectives Identify categories of diabetes medications Understand the pharmacology of diabetes
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationDiabetes, Drugs and Dangerous Discrepancies. Sally Bodenhamer, OD, OT/L, CDE
Diabetes, Drugs and Dangerous Discrepancies Sally Bodenhamer, OD, OT/L, CDE I have no disclosures Disclosures $245 BILLION American DM ASSOC 2012 cost of Diabetes Economic Costs of Diabetes in the U.S.
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationAACN PCCN Review. Endocrine
AACN PCCN Review Endocrine Presenter: Carol A. Rauen, RN, MS, CCNS, CCRN, PCCN, CEN Independent Clinical Nurse Specialist & Education Consultant rauen.carol104@gmail.com Endocrine I. INTRODUCTION Disorders
More informationBlood Glucose Monitoring
Blood Glucose Monitoring What is Glucose? A simple sugar that enters the diet as part of sucrose, lactose, or maltose Part of a polysaccharide called dietary starch Most of the body s energy comes from
More information第十五章. Diabetes Mellitus
Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationNph insulin conversion to lantus
Nph insulin conversion to lantus Search 26-2-2003 RESPONSE FROM AVENTIS. We appreciate the opportunity to respond to Dr. Grajower s request for information regarding Lantus ( insulin glargine [rdna origin.
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationPharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN
Pharmacology Kacy Aderhold, MSN, APRN-CNS, CMSRN Biguanides Decreases hepatic glucose production and improves insulin sensitivity (increases number of insulin receptors) Common Adverse Reaction: diarrhea
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationDiabetes School October 2016
Diabetes School October 2016 Name Change- Why? Shorter Has my name in it Emphasizes a major part of the practice Still see non-research patients Novo Nordisk Lilly sanofi aventis! Thank You to our LucasResearch
More informationTherapy of Diabetes Mellitus
2016 edition by Jayne S. Reuben, PhD Department of Biomedical Sciences University of South Carolina School of Medicine Greenville Originally developed by Elliott Chideckel, MD Department of Medicine Robert
More informationMaking Sense of Mediations for Diabetes
Making Sense of Mediations for Diabetes Lisa Kroon, PharmD, CDE Professor of Clinical Pharmacy UCSF School of Pharmacy Diabetes Mellitus: U.S. Impact Source: ADA; released June 10, 2014 ~1-1.5 Million
More information